Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 3Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Resectable Non-Small Cell Lung Cancer 1Pancreatic Neoplasms 1Lung Neoplasms 1

Interventions

Carboplatin 18Radiotherapy 10Cisplatin 10Pemetrexed 8Paclitaxel 8durvalumab 6Magnetic Resonance Spectroscopy 6Gemcitabine 6Radiosurgery 5Nivolumab 5Etoposide 5pembrolizumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Erlotinib Hydrochloride 4Docetaxel 4Taxes 3Standard of Care 3Specimen Handling 3Platinum 3Cetuximab 3Bronchoscopy 3Biopsy 3Bevacizumab 31,2-diaminocyclohexaneplatinum II citrate 3sapanisertib 2etoposide phosphate 2capmatinib 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × adagrasib × Clear all
NCT05848843 2024-01-23

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡